阻塞性睡眠呼吸暂停:一个不断发展的治疗景观,以创基疗法的新兴作用
Bolong Xu1, Kaveh Gaynor-Sodeifi2, Vaishnavi Kundel3
1Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Advances in therapy
|July 23, 2025
概括
阻塞性睡眠呼吸暂停 (OSA) 治疗正在发展. 蒂尔泽帕提德是一种基于隐素的药物,它通过帮助减肥和改善症状来治疗与肥胖相关的OSA,提供了一个新的治疗选择.
科学领域:
- 睡眠医学 睡眠医学
- 心血管疾病 心血管疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种普遍存在的疾病,与肥胖和心血管风险有关.
- 目前的治疗方法,如正气道压力 (PAP),在坚持和长期结果方面存在局限性.
- 了解OSA多样化的生理驱动因素对于开发新疗法至关重要.
研究的目的:
- 审查目前和新兴的阻塞性睡眠呼吸暂停的治疗方法.
- 强调针对OSA的个性化管理策略.
- 突出基于隐素的疗法在OSA治疗中的作用.
主要方法:
- 关于OSA治疗策略的综合文献综述.
- 分析最近的治疗进展,包括药理干预措施.
- 关注OSA管理的个性化医疗方法.
主要成果:
- 传统的OSA疗法具有不同的疗效和坚持.
- 针对特定OSA特征的新型疗法正在研究中.
- 蒂尔泽帕提德是一种基于隐素的药物,在治疗与肥胖相关的OSA方面表现出有效性.
结论:
- 对于OSA的治疗场景正在迅速发展.
- 个性化治疗策略对于有效的OSA管理至关重要.
- 基于因克雷丁的疗法,如蒂尔泽帕提德,代表了OSA治疗的重大进步.
相关概念视频
Sleep Apnea
224
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
224
Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
Management of Insomnia
323
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
323
Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
Gastroesophageal Reflux Disease II: Clinical Features and Management
217
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
217


